Scilex Hit With Nasdaq Notice: Market Value Below $35M Minimum, All Three Listing Standards Failed
SCLX is trading near its 52-week low of $0.5 (13% above the low) on elevated volume (3.5× avg).
Summary
Scilex received a Nasdaq notice that its market value has been below the $35 million minimum and that it fails the alternative equity and net income standards. It has until May 17, 2027 to regain compliance or face a delisting determination it can appeal.
Key Events · Legal and Risk Events · SCLX
-
Nasdaq MVLS Deficiency Notice Received
Nasdaq notified Scilex on November 17, 2026 that market value of listed securities was below the $35 million minimum for the 30 business days from October 6 through November 16, 2026.
-
All Alternative Listing Standards Also Failed
The notice states Scilex also does not meet Nasdaq Rules 5550(b)(1) (minimum stockholders' equity) or 5550(b)(3) (net income from continuing operations), so no alternate route to compliance is available.
-
180-Day Cure Window to May 17, 2027
Under Rule 5810(c)(3)(C) the company has until May 17, 2027; closing at $35 million or more for ten consecutive business days restores compliance, though Nasdaq may require up to 20 days.
-
Delisting Appeal Path If Not Cured
If compliance is not regained by the deadline, Nasdaq will issue a delisting determination, which Scilex may appeal to a Nasdaq Hearings Panel. Shares and warrants continue trading as SCLX and SCLXW meanwhile.
Analysis · SCLX · Life Sciences
The stakes are high: Scilex learned on November 17 that its listed securities' market value had sat below the $35 million Nasdaq Capital Market minimum for 30 straight business days, and it also misses the alternative stockholders' equity and net income tests. With a going-concern warning already in place and only $0.6 million of cash, a listing deficiency strips away a safety net the company cannot easily rebuild. Trading continues for now, and the company has until May 17, 2027 to close at $35 million or more for at least ten consecutive business days; failing that, Nasdaq issues a delisting determination that Scilex can appeal to a Hearings Panel. The notice lands two days after the company disclosed replacing its auditor, adding to a run of governance and survival concerns.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCLX was trading at $0.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $0.50 to $16.81. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.